News

Applied Clinical Trials Online15h
MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes
In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...
Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues
Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.
BioPharma Dive13h
New Amgen obesity drug data disappoint Wall Street
Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...
Fierce Biotech15h
Amgen rolls out phase 3 dosing plan for lead obesity candidate after midstage trial sees high discontinuation, vomiting rates
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
STAT1d
Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
Devdiscourse1d
Amgen's MariTide: Promising Weight Loss with Milder Side Effects
Amgen's experimental obesity drug MariTide showed promising weight loss results with fewer side effects, according to a ...
Amgen experimental weight-loss drug needs lower dose to limit side effects
Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...
New Data Shows Just How Powerful the Next Weight-Loss Drugs May Be
Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...
Lilly, Novo, and Amgen set for key obesity trial readouts at upcoming ADA event
Novo Nordisk (NVO), and Amgen (NASDAQ:AMGN) are scheduled to present major clinical trial readouts at the American Diabetes ...